What is RLMD's current stock price?

RLMD (Relmada Therapeutics, Inc.) is currently trading at $6.98 with a market cap of $512.2M.

What sector is Relmada Therapeutics, Inc. in?

Relmada Therapeutics, Inc. (RLMD) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is RLMD a good stock to buy?

Analysts have a Buy consensus on RLMD with a price target of $9.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

RLMD Relmada Therapeutics, Inc.

Healthcare

$6.98+0.00%OpenMarket Cap: $512.2M

As of 2026-05-26

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

2.79

P/S

0.00

EV/EBITDA

-8.39

DCF Value

$0.05

FCF Yield

-8.3%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-71.2%

ROA

-25.0%

ROIC

-27.1%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-19.1M	$—
Q4 null	$0.00	$-19.9M	$—
FY null	$0.00	$-57.4M	$—
Q3 null	$0.00	$-10.1M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$9.00

Target (Median)

$9.00

Target Range

$8.00 - $10.00

1 Strong Buy4 Buy0 Hold0 Sell0 Strong Sell

MizuhoOutperform

2026-03-20

Leerink PartnersOutperform

2026-01-23

MizuhoOutperform

2025-11-19

Trading Activity

Insider Trades

View All

TRAVERSA SERGIOdirector, officer: Chief Executive Officer

BuyTue Dec 16

TRAVERSA SERGIOdirector, officer: Chief Executive Officer

SellTue Dec 16

Shenouda Magedofficer: Chief Financial Officer

BuyTue Dec 16

Shenouda Magedofficer: Chief Financial Officer

SellTue Dec 16

Kelly Paul Edwarddirector, officer: COO

SellTue Dec 16

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.43

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.

Peers